Table 3:
Multivariable analysis for overall survival comparing the 8 HRR gene mutation carriers to non-carriers#.
| Number of Events/Total | Median Survival in months (95% CI) | Multivariable Analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P-value | |||
| Overall: | 0.02 | |||
| Non-Carrier | 2441/2730 | 11.7 (11.2–12.4) | Reference | |
| Carrier | 154/175 | 14.6 (13.2–16.1) | 0.83 (0.70–0.97) | |
| Subset Analysis: | ||||
| Non-resectable or metastatic | 0.02 | |||
| Non-Carrier | 1839/2028 | 9.6 (9.1 – 10.2) | Reference | |
| Carrier | 118/127 | 8.0 (5.8–12.2) | 0.81 (0.67 – 0.97) | |
| Surgically resected | 0.49 | |||
| Non-Carrier | 565/692 | 23.5 (21.7 – 25.2) | Reference | |
| Carrier | 34/46 | 23.7 (18.4 – 45.8) | 0.89 (0.63 – 1.25) | |
| Diagnosed prior to May 2011 | 0.22 | |||
| Non-Carrier | 1650/1741 | 10.4 (9.7–11.0) | Reference | |
| Carrier | 105/114 | 13.8 (10.6–16.1) | 0.89 (0.73–1.08) | |
| Diagnosed May 2011 or later | 0.04 | |||
| Non-Carrier | 791/989 | 13.7 (13.1–14.3) | Reference | |
| Carrier | 49/61 | 15.7 (12.4–20.5) | 0.75 (0.56–1.00) | |
| Received platinum-based chemotherapy | 0.18 | |||
| Non-Carrier | 597/700 | 16.3 (15.6–17.2) | Reference | |
| Carrier | 54/61 | 17.8 (16.0–22.1) | 0.83 (0.63–1.10) | |
| Did not receive platinum-based chemotherapy | 0.20 | |||
| Non-Carrier | 1838/2022 | 9.7 (9.1 – 10.2) | Reference | |
| Carrier | 98/112 | 11.5 (8.3 – 14.0) | 0.88 (0.72 – 1.08) | |
| Diagnosed prior to May 2011 and did not receive platinum-based chemotherapy | 0.34 | |||
| Non-Carrier | 1402/1485 | 9.3 (8.6 – 9.9) | Reference | |
| Carrier | 81/89 | 10.1 (8.0 – 14.0) | 0.90 (0.72 – 1.13) | |
| Diagnosed prior to May 2011 and received platinum-based chemotherapy | 0.43 | |||
| Non-Carrier | 243/249 | 15.6 (14.5–17.4) | Reference | |
| Carrier | 22/23 | 17.8 (15.0–45.8) | 0.84 (0.54–1.31) | |
| Diagnosed May 2011 or later & received platinum-based chemotherapy | 0.24 | |||
| Non-Carrier | 354/451 | 16.7 (15.9–17.5) | Reference | |
| Carrier | 32/38 | 19.7 (15.4–22.3) | 0.81 (0.56–1.17) | |
| Diagnosed May 2011 or later and received FOLFIRINOX | 0.43 | |||
| Non-Carrier | 246/322 | 17.4 (16.6–20.0) | Reference | |
| Carrier | 28/32 | 17.7 (12.4–28.5) | 0.85 (0.57–1.27) | |
| Diagnosed May 2011 or later and received irinotecan | 0.41 | |||
| Non-Carrier | 291/382 | 17.3 (16.6–19.3) | Reference | |
| Carrier | 30/35 | 17.7 (12.4–25.0) | 0.85 (0.58–1.25) | |
| Non-resectable/metastatic and received platinum-based chemotherapy | 0.12 | |||
| Non-Carrier | 490/591 | 15.4 (14.1 – 16.6) | Reference | |
| Carrier | 42/47 | 17.5 (14.6 – 21.8) | 0.78 (0.57 – 1.07) | |
| Surgically resected and received platinum-based chemotherapy | 0.86 | |||
| Non-Carrier | 106/107 | 22.9 (20.1 – 27.1) | Reference | |
| Carrier | 12/14 | 23.7 (17.7 – NE) | 1.06 (0.57 – 1.95) | |
| Subset analysis by mutation carrier status in each gene€ | ||||
| Non-carriers | 2441/2730 | 11.7 (11.2–12.4) | Reference | |
| ATM carriers | 57/65 | 15.7 (14.4–21.1) | 0.72 (0.55–0.94) | 0.01 |
| BRCA1 carriers | 19/20 | 9.2 (5.8–16.1) | 1.26 (0.80–1.98) | 0.34 |
| BRCA2 carriers | 58/67 | 15.0 (11.5–20.0) | 0.81 (0.62–1.05) | 0.10 |
| PALB2 carriers | 10/12 | 14.2 (12.4–66.9) | 0.74 (0.40–1.38) | 0.33 |
| Subset analysis by receipt of platinum-based chemotherapy among mutation carriers | ||||
| Did not receive platinum-based chemotherapy | 76/80 | 7.7 (5.8 – 10.1) | Reference | |
| Received platinum-based chemotherapy | 42/47 | 17.5 (14.6 – 21.8) | 0.46 (0.30 – 0.68) | <0.001 |
CI: Confidence Interval; FOLFIRINOX: Regimen consisting of fluorouracil, leucovorin, irinotecan and oxaliplatin;
#
: Analyses were adjusted for age at diagnosis, sex, and stage at diagnosis (where appropriate);
€
: Survival in carriers of germline mutations in each of the 8 homologous recombination repair genes compared to non-carriers; Hazard ratios for genes with less than 5 mutation carriers not estimated.
NE not estimable